Covid-19 at the Regional Medical Center Metz-Thionville: a Descriptive Study (COMETE-19)

Coronavirus Disease 2019 (Covid-19) at the Regional Hospital Center Metz-Thionville: a Descriptive Study

France and especially the region "Grand Est" have been damaged by the COVID-19 pandemic. This pandemic resulted in a reorganization of the hospitalization sectors.

In order to better understand the disease, the investigators wish to carry out a descriptive analysis of hospitalized patient data. This study would notably allow us to identify some prognostic factors.

The main objective of this study is to identify individual factors that are associated with a poor prognosis (with ICU admission or death).

Study Overview

• Status: Completed
• Conditions: COVID

• Study Type: Observational
• Enrollment (Actual): 1045

Contacts and Locations

• Study Contact: Name: Rostane GACI, MD; Phone Number: 0033 387186220; Email: r.gaci@chr-metz-thionville.fr
• Study Contact Backup: Name: Vincent DINOT; Phone Number: 0033 387553323; Email: vincent.dinot@gmail.com

Study Locations

• France
  • Metz, France, 57085
    • CHR Metz Thionville

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patient hospitalized in COVID Unit at the Regional Hospital Center Metz-Thionville during the COVID-19 pandemic with a PCR positive or COVID confirmed with clinical evidence and CT scan.

Description

Inclusion Criteria:

• Patient hospitalized in COVID Unit at the Regional Hospital Center Metz-Thionville during the COVID 19 pandemic
• PCR positive or COVID confirmed with clinical evidence and CT scan

Exclusion Criteria:

• Patients not willing to participate via using their medical files
• Patient transferred after a brief stay in another hospital

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ICU admission	Number of ICU admission during the hospitalization	Day 1

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hospitalization	The duration of the hospitalization	Day 1
Length of stay at the ICU	The duration of stay at the ICU	Day 1
Death	The occurrence of death during the stay	Day 1
CT scan result	Evocative CT scan result	Day 1
C reactive protein	C reactive protein value	Day 1
Blood Count	Blood Count value	Day 1
Sodium	Sodium value	Day 1
Urea	Urea value	Day 1
Troponine	Troponine value via biological data	Day 1
Liver function	Transaminases value	Day 1
Coagulation test	Quick test result	Day 1
Creatinine	creatinine value	day 1
Clearance	creatinine clearance value	day 1
Potassium	potassium value	day 1
Calcium	calcium value	day 1
Gamma-glutamyl transpeptidase	Gamma-glutamyl transpeptidase value	day 1
Bilirubine	Bilirubine value	day 1
Alcaline phosphatase	Alcaline phosphatase value	Day 1
Prothrombine	Prothrombine value	Day 1

Collaborators and Investigators

• Sponsor: Centre Hospitalier Régional Metz-Thionville

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2020
• Primary Completion (Actual): June 1, 2022
• Study Completion (Actual): June 1, 2022

Study Registration Dates

• First Submitted: June 11, 2020
• First Submitted That Met QC Criteria: June 11, 2020
• First Posted (Actual): June 12, 2020

Study Record Updates

• Last Update Posted (Actual): August 29, 2023
• Last Update Submitted That Met QC Criteria: August 28, 2023
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Other Study ID Numbers: 2020-02Obs-CHRMT

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No